Abstract
In normal man, glucose serves to regulate basal insulin secretion by its participation with insulin in a feedback loop. In addition, glucose stimulates insulin secretion directly and potentiates insulin responses to nonglucose stimuli such as amino acids, 8-adrenergic stimuli, and gut hormones. Maximal glycemic potentiation of the acute insulin response to IV arginine occurs at a glucose level of approx. 450 mg/dl.
In patients with noninsulin dependent diabetes mellitus (NIDDM), basal insulin levels have usually been reported as normal, but if plasma glucose is lowered to normal levels, a deficiency of basal insulin becomes apparent. In addition, the first phase (0-10 min) insulin response to IV glucose is absent in virtually all patients with overt NIDDM. In contrast, the second-phase (> 10 min) response is often preserved in NIDDM due to its maintenance by ambient hyperglycemia. Similarly, insulin responses to nonglucose stimuli such as arginine often appear normal in NIDDM because of potentiation by hyperglycemia. However, insulin responses to arginine are lower than those of nondiabetic controls when compared at multiple matched glucose levels. Indeed, maximal potentiation by glucose of the insulin response to arginine is markedly subnormal in NIDDM, suggesting a loss of functional B cell secretory capacity.
In patients with long-standing insulin-dependent diabetes mellitus (IDDM), basal insulin secretion and insulin responses to all stimuli are virtually absent. However, in a remission phase, or in IDDH of short duration, basal insulin secretion and insulin responses to nonglucose stimuli may be relatively preserved. Therefore, islet dysfunction in IDDH and NIDDH, while etiologically different, share some common pathophysiological features.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
C.H. Asplin, T. L. Paquette, and J.P. Palmer, In vivo inhibition of glucagon secretion by paracrine beta cell activity in man, J Clin Invest 68:314–318 (1981).
J.D. Bagdade, E.L. Bierman, and D. Porte, Jr., The significance of basal insulin in the evaluation of the insulin response to glucose in diabetic and non-diabetic subjects, J Clin Invest 46: 1549–1557 (1967).
J.C. Beard, J.D. Best, H.A. Pfeifer, J.S. Halter, and D. Porte, Jr., Corticosteroids alter B-cell sensitivity to hyperglycemia in man, Clin Res 30: 522A (1982).
J.C. Beard, C. Weinberg, H.A. Pfeifer, J.D. Best, J.B. Halter, and D. Porte, Jr., Interaction of glucose and epinephrine in the regulation of insulin secretion, Diabetes 31: 802–807 (1982).
J.R. Brooks, Operative approach to pancreative carcinoma, Seminars in Oncology 6: 357–367 (1979).
J.D. Brunzell, R.P. Robertson, R.L. Lerner, H.R. Hazzard, J.W. Ensinck, E.L. Bierman, and D. Porte, Jr., Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests, J Clin Endocrinol Metab 42: 222–229 (1976).
E. Cerasi, Potentiation of insulin release by glucose in man. I. Quantitative analysis of the enchancement of glucose-induced insulin secretion by pretreatment with glucose in normal subjects, Acta Endocrinol 79: 483–501 (1975).
E. Cerasi, R. Luft, and S. Efendic, Decreased sensitivity of the pancreatic beta cells to glucose in prediabetic subjects, Diabetes 21: 224–234 (1972).
H. Chen, D. Porte, Jr., The effect of rate and dose of glucose infusion on the acute insulin response in man, J Clin Endocrinol Metab 42:1168–1175 (1976).
E.W. Chideckel, J. Palmer, D.J. Koerker, J. Ensinck, H.B. Davidson, and C.J. Goodner, Somatostatin blockade of acute and chronic stimuli of the endocrine pancreas and the consequences of this blockade on glucose homeostasis, J Clin Invest 55: 754–762 (1975)
D.L. Curry, L.L. Bennett, and G.H. Grodsky, Dynamics of insulin secretion by the perfused rat pancreas, Endocrinolgy 83: 572–578 (1968).
R.A. DeFronzo, J.D. Tobin, and R. Andres, Glucose clamp technique: a method for quantifying insulin secretion and resistance, AM J Physiol 237 (3): E214–E223 (1979).
A. Drash, J.B. Field, L.Y. Garces, F.H. Kenny, D. Mintz, and A.H. Vazquez, Endogenous insulin and growth hormone response in children with newly-diagnosed diabetes mellitus, Pediat Res 2: 94–102 (1968).
D. Drucker and B. Zinman, Pathophysiology of beta-cell failure after prolonged remission in insulin-dependent diabetes mellitus, Diabetes Care 1: 83–87 (1984).
J. Dupre, J.D. Curtis, R.H. Unger, R.W. Waddell, and J.C. Beck, Effects of secretin, pancreozymin, or gastrin on the response of the endocrine pancreas to administration of glucose or arginine in man, J Clin Invest 48: 745–757 (1969).
G.S. Eisenbarth, Immunotherapy of type 1 diabetes (editorial), Diabetes Care 6: 521–523 (1983).
H. Elrick, Plasma insulin responses to oral and intravenous glucose administration, J Clin Endocrinol 24: 1076–1082 (1964).
O.K. Faber, and C. Binder, B-cell function and blood glucose control in insulin-dependent diabetics within the first month of insulin treatment, Diabetologia 13: 263–268 (1977).
O.K. Faber, and C. Binder, C-peptide response to glucagon. A test for the residual B-cell function in diabetes mellitus, Diabetes 26: 604–610 (1977).
S.S. Fajans, J.C. Floyd, R.F. Knopf, and J.W. Conn, A comparison of leucine-and acetoacetate-induced hypoglycemia in man, J Clin Invest 43: 2003–2008 (1964).
P. Felig, E.B. Marliss, and G.F. Cahill Jr., Metabolic response to human growth hormone during prolonged starvation, J Clin Invest 50: 411–421 (1971).
P. Felig, J. Wahren and R. Hendler, Influence of maturity-onset diabetes on splanchnic glucose balance after oral glucose ingestion, Diabetes 27: 121–131 (1978).
J.D. Fitz, E.H. Sperling and H.G. Fein, A hypocaloric high-protein diet as primary therapy for adults with obesity-related diabetes, Diabetes Care 6: 328–333 (1983).
J.C. Floyd, Jr., S.S. Fajans, J.W. Conn, R.F. Knopf, and J. Rull, Stimulation of insulin secretion by amino acids, J Clin Invest 45: 1487–1502 (1966).
W. Gepts and P.M. Lecompte, The pancreatic islets in diabetes, Amer J Med 70: 105–114 (1981).
D. Giugliano, A. Ceriello, P. DiPinto, Impaired insulin secretion in human diabetes mellitus: the effect of naloxone- induced opiate receptor blockade, Diabetes 31: 367–370 (1982).
C.J. Goodner, M.J. Conway and J. H. Werrbach, Control of insulin secretion during fasting hyperglycemia in adult diabetics and in nondiabetic subjects during infusion of glucose, J Clin Invest 48: 1878–1889 (1969).
C.J. Goodner and D. Porte, Jr., Determinants of basal isletsecretion in man. in: “Handbook of Physiology; Endocrinology; Endocrine Pancreas, Chapter 38,” Steiner DF, Freinkel N (eds), Washington DC, Am Physiol Soc, (1972) pp 597–609.
G.M. Grodsky and L. L. Bennett, Multiphasic aspects of insulin release after glucose and glucagon, in: “Diabetes,” J. Ostman, ed., Proc Sixth Cong Int Diabetes Fed, (1969), pp 462–469, Excerpta Medica Foundation, Amsterdam.
J.B. Halter, R.J. Graf and D. Porte, Jr., Potentiation of insulin secretory responses by plasma glucose levels in man: Evidence that hyperglycemia in diabetes compensates for impaired glucose potentiation, J Clin Endocrinol Metab 48: 946–954 (1979).
J.B. Halter and D. Porte, Jr., Mechanisms of impaired acute insulin release in adult onset diabetes: Studies with isoproterenol and secretin, J Clin Endocrinol Metab 46: 952–960 (1978).
E. Heinze, W. Beisher, L. Keller, G. Winkler, W.M. Teller, and E.F. Pfeiffer, C-peptide secretion during the remission phase of juvenile diabetes, Diabetes 27: 670–676 (1978).
C. Hendriksen, O.K. Faber, J. Drejer, and C. Binder, Prevalence of residual B-Cell function in insulin-treated diabetics evaluated by the plasma C-peptide response to intravenous glucagon, DiabetoloRia 13: 615–619 (1977).
C.B. Hollebneck, Y-D.I. Chen, and G.M. Reaven, A Comparison of the relative effects of obesity and noninsulin dependent diabetes mellitus on in vivo insulin stimulated glucoase utilization, Diabetes 33: 622–626 (1984).
R.R. Holman and R.C. Turner, Maintenance of basal plasma glucose and insulin concentrations in maturity-onset diabetes, Diabetes 28: 227–230 (1979).
H. Kajinuma, A. Kaneto, T. Kuzuya, and K. Nakao, Effects of methacholine on insulin secretion in man, J Clin Invest 28: 1384–1388 (1968).
S.C. Kalhan and P.A.J. Adam, Inhibitory effect of prednisone on insulin secretion in man: model for duplication of blood glucose concentration, J Clin Endocrinol Metab 41: 600–610 (1975).
J.H. Karam, G.M. Grodsky, K.N. Ching, Staircase glucose stimulation of insulin secretion in obesity, Diabetes 23: 763–770 (1974).
J.L. Leahy, S. Bonner-Weir, and G. Weir, Abnormal glucose regulation of insulin secretion in models of reduced B-cell mass, Diabetes 33: 667–673 (1984).
R.J. Lerner and D. Porte, Jr., Studies of secretin-stimulated insulin responses in man, J Clin Invest 51: 2205–2209 (1972).
R.J. Lerner and D. Porte, Jr., Acute and steady-state insulin responses to glucose in nonobese diabetic subjects, J Clin Invest 51: 1624–1631 (1972).
S.R. Levin, J.H. Karam, S. Kane, G.H. Grodsky, and P.H. Forsham, Enhancement of arginine-induced insulin secretion in man by prior administration of glucose. Diabetes 20: 171–176 (1971).
J. Ludvigsson and L.G. Heding, C-peptide in diabetic children after stimulation with glucagon compared with fasting C-peptide levels in non-diabetic children, Act Endocrinologica 85: 364–371 (1977).
J.A. Lutterman, T.J. Benraad, and A. Vantlaar, The relationship between residual insulin secretion and metabolic stability in Type 1 diabetes, Diabetologia 21: 99–103 (1981).
S. Madsbad, T. Krarup, O.K. Faber, C. Binder, and L. Regeur, The transient effect of strict glycemic control on B-cell function in newly-diagnosed type 1 diabetic patients, Diabetologia 22: 16–20 (1982).
J.R. McRae, S.A. Metz, and R.P. Robertson, A role for endogenous prostaglandins in defective glucose potentiation of nonglucose insulin secretagogues in diabetics, Metabolism 30: 1065–1075 (1981).
S.A. Metz, J.B. Halter, and R.P. Robertson, Paradoxical inhibition of insulin secretion by glucose in human diabetes mellitus, J Clin Endocrinol Metab 48: 827–835 (1979).
J. Mirouze, J.L. Selam, T.C. Pham, E. Mendoza, and A. Orsetti, Sustained insulin-induced remissions of juvenile diabetes by means of an external pancreas, Diabetologia 14: 223–227 (1978).
R.L. Parker, R.S. Pildes, K.L. Chao, M. Cornblath, and D.H. Kipnis, Juvenile diabetes mellitus, a deficiency in insulin, Diabetes 17: 27–35 (1968).
H.J. Perley and D.H. Kipnis, Plasma insulin responses to oral and intravenous glucose: Studies in normal and diabetic subjects, J Clin Invest 46: 1954–1962 (1967).
M.A. Pfeifer, J.B. Halter, and D. Porte, Jr., Insulin secretion in diabetes mellitus, Am J Med 70: 579–588 (1981).
D. Porte Jr. and A.A. Pupo, Insulin responses to glucose: evidence for a two-pool system in man, J Clin Invest 48: 2309–2319 (1969).
D. Porte Jr., and R.H. Williams, Inhibition of insulin release by norepinephrine in man, Science 152: 1248–1250 (1966).
G.H. Reaven, E. Bernstein, B. Davis, and J. M. Olefsky, Nonketotic diabetes mellitus: insulin deficiency or insulin resistance? Am J Ned 68: 80–86 (1976).
J.F. Rehfield and F. Stadil, The effect of gastrin on basal and glucose-stimulated insulin secretion in man, J. Clin Invest 52: 1415–1426 (1973).
R.P. Robertson and M. Chen, A role for prostaglandin E (PGE) in defective insulin secretion and carbohydrate intolerance in diabetes mellitus, J Clin Invest 60: 747–753 (1977).
R.P. Robertson, J.B. Halter, and D. Porte, Jr., A role for alpha-adrenergic receptors in abnormal insulin secretion in diabetes mellitus, J Clin Invest 57: 791–795 (1976).
K. Saito, N. Yaginuma, and T. Takahashi, Differential volumetry of A,B, and D cells in the pancreatic islets of diabetic and nondiabetic subjects, Tohoku J Exp med129: 273–283 (1979).
E. Samols, G. Marri, and V. Marks, Promotion of insulin secretion by glucagon, Lancet 2: 415–416 (1965).
M. Schebalin, S.I. Said and G.M. Makhlouf, Stimulation of insulin and glucagon secretion by vasoactive intestinal peptide, Am J Physiol 232: E197–E200 (1977).
K. Shima, R. Tanaka, S. Morishita, Studies on the etiology of brittle diabetes: relationship between diabetic instability and insulinogenic reserve, Diabetes 26: 717–725 (1977).
S. Srikanta, O.P. Ganda, R. A. Jackson, R.E. Gleason, A. Kaldany, H.R. Garavoy, E.L. Milford, C.B. Carpenter, J.S. Soeldner, and G.S. Eisenbarth, Type 1 diabetes mellitus in monozygotic twins: chronic progressive beta cell dysfunction, Annals Int Med 99: 320–326 (1983).
C.R. Stiller, J. Dupre, M. Gent, Effect of cyclosporine in type 1 diabetes: clinical course and immune response, Diabetes 33 (Suppl 1): 13A (1984).
R.C. Turner, R.R. Holman, D. Matthews, T.D.R. Hockaday, and J. Peto, Insulin deficiency and insulin resistance interaction in diabetes: estimation of their relative contribution by feed- back analysis from basal plasma insulin and glucose concentrations, Metabolism 28: 1086–1096 (1979).
R.C. Turner, S.T. McCarthy, R.R. Holman, and E. Harris, Beta-cell function improved by supplementary basal insulin secretion in mild diabetes, Brit Med J1: 1252–1254 (1976).
C.A. Verdonk, R.A. Rizza, R.L. Nelson, Y.L.W. Go, J.E. Gerich, and F.J. Service, Interaction of fat-stimulated gastric inhibitory polypeptide on pancreatic alpha and beta-cell function, J Clin Invest 66: 1119–1125 (1980).
W.K. Ward, J.C. Beard, J.B. Halter, M. A. Pfeifer and D. Porte, Jr., Pathophysiology of insulin secretion in noninsulin dependent diabetes mellitus, Diabetes Care 7: 491–502 (1984).
W.K. Ward, D.C. Bolgiano, B. McKnight, J.B. Halter, and D. Porte, Jr., Diminished B-cell secretory capacity in patients with noninsulin dependent diabetes mellitus, J Clin Invest 74: 1318–1328 (1984).
W.K. Ward, J.B. Halter, J.D. Best, J.C. Beard, and D. Porte, Jr., Hyperglycemia and B-cell adaptation during prolonged somatostatin infusion in man, Diabetes 32: 943–947 (1983).
W.K. Ward, J.B. Halter, J.C. Beard, and D. Porte, Jr., Adaptation of B and A-cell function during prolonged glucose infusion in human subjects, Am J Physiol 246 (Endocrinol Metab) E405–E411 (1984).
K.W. Warren, J.W. Braasch, and C.W. Thurn, Diagnosis and surgical treatment of carcinoma of the pancreas, Curr Probl Surs 132: 3–70 (1968).
T.A. Welborn, P. Garcia-Webb, and A.M. Bonser, Basal C-peptide in the discrimination of Type I from Type II diabetes, Diabetes Care 4: 616–619 (1981).
P. Westermark and E. Wilander, The influence of amyloid deposits on the islet volume in maturity-onset diabetes mellitus, Diabetologia 15: 417–421 (1978).
D.K. Yue, R.C. Baxter, and J. R. Turtle, C-peptide secretion and insulin antibodies as determinants of stability in diabetes, Metabolism 27: 35–44 (1978).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Springer Science+Business Media New York
About this chapter
Cite this chapter
Ward, W.K., Beard, J.C., Halter, J.B., Porte, D. (1985). Pathophysiology of Insulin Secretion in Diabetes Mellitus. In: Vranic, M., Hollenberg, C.H., Steiner, G. (eds) Comparison of Type I and Type II Diabetes. Advances in Experimental Medicine and Biology, vol 189. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-1850-8_9
Download citation
DOI: https://doi.org/10.1007/978-1-4757-1850-8_9
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-1852-2
Online ISBN: 978-1-4757-1850-8
eBook Packages: Springer Book Archive